Cyclerion Therapeutics, Inc (CYCN)

In this article, we discuss the top stocks recently acquired by David Greenspan’s Slate Path Capital according to analysts. If you want to skip our detailed analysis of Greenspan’s history, investment philosophy, and hedge fund performance, go directly to David Greenspan’s Slate Path Capital is Buying These 5 Stocks. David Greenspan instilled his efforts at […]

Every investor in Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) should be aware of the most powerful shareholder groups...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:TENB) from Hold to Buy. In the second quarter, Tenable ...

Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment

Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairmentCAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administration of a small molecule soluble guanylate cyclase (sGC) stimulator reduced markers associated with neuroinflammation in multiple precli

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer’s disease therapies

Gainers Strata Skin Sciences (NASDAQ:SSKN) stock increased by 11.27% to $1.48 during Monday's after-market session. Today's trading ...

Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently ...

Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired ...

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism ...

Cyclerion Therapeutics Inc (NASDAQ: CYCN) shares are trading higher Friday morning after the company announced it will present a trial ...

Gainers Acorda Therapeutics (NASDAQ:ACOR) stock moved upwards by 56.69% to $5.97 during Friday's pre-market session. ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're gearing up for one final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Gainers Socket Mobile Inc (NASDAQ: SCKT) shares rose 100.2% to $11.61 in pre-market trading after the company reported ...

Gainers Twitter (NYSE: TWTR) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results ...

Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion’s investigational therapeutics

Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion’s investigational therapeuticsCAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that it will present clinical trial design for a Phase 2a study of its lead development candidate, CY6463, in particip

Investors in Cyclerion Therapeutics Inc (CYCN) saw new options begin trading this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYCN options chain for the new September 17th contracts and identified one put and one call contract of particular interest.

It is a pleasure to report that the Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) is up 34% in the last quarter. But...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Cyclerion Therapeutics Inc(NASDAQ: CYCN) andBeacon Biosignalshave expanded strategic partnershipsbetween the ...

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment.

Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases associated with cognitive impairment

Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. ...